Role  	Role  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
incretin  	incretin  	 JJ	B-NP
pathway  	pathway  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
pathogenesis  	pathogenesis  	 NN	B-NP
of  	of  	 IN	O
type  	type  	 NN	O
2  	2  	 CD	O
diabetes  	diabetes  	 FW	B-NP
mellitus  	mellitus  	 FW	I-NP
Nutrient  	Nutrient  	 FW	I-NP
intake  	intake  	 FW	I-NP
stimulates  	stimulates  	 FW	O
the  	the  	 DT	O
secretion  	secretion  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
gastrointestinal  	gastrointestinal  	 JJ	I-NP
incretin  	incretin  	 JJ	I-NP
hormones 	hormones 	 NNS	I-NP
,  	,  	 ,	O
glucagon-like  	glucagon-like  	 NNP	B-NP
peptide-1  	peptide-1  	 NNP	I-NP
( 	( 	 -LRB-	O
GLP-1 	GLP-1 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
glucose-dependent  	glucose-dependent  	 JJ	B-NP
insulinotropic  	insulinotropic  	 JJ	I-NP
polypeptide  	polypeptide  	 NNS	I-NP
( 	( 	 -LRB-	O
GIP 	GIP 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
which  	which  	 WDT	O
exert  	exert  	 VBZ	O
glucose-dependent  	glucose-dependent  	 JJ	B-NP
insulinotropic  	insulinotropic  	 JJ	I-NP
effects  	effects  	 NNS	I-NP
and  	and  	 CC	O
assist  	assist  	 VB	O
pancreatic  	pancreatic  	 JJ	B-NP
insulin  	insulin  	 NN	I-NP
and  	and  	 CC	O
glucagon  	glucagon  	 NN	B-NP
in  	in  	 IN	O
maintaining  	maintaining  	 VBG	B-NP
glucose  	glucose  	 JJ	I-NP
homeostasis 	homeostasis 	 NN	I-NP
.  	.  	 .	O
GLP-1  	GLP-1  	 NNP	B-NP
also  	also  	 RB	O
suppresses  	suppresses  	 JJ	O
glucose-dependent  	glucose-dependent  	 JJ	B-NP
glucagon  	glucagon  	 JJ	I-NP
secretion 	secretion 	 NN	I-NP
,  	,  	 ,	O
slows  	slows  	 VBZ	O
gastric  	gastric  	 JJ	B-NP
emptying 	emptying 	 NN	I-NP
,  	,  	 ,	O
increases  	increases  	 VBZ	O
satiety 	satiety 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
reduces  	reduces  	 JJ	O
food  	food  	 NN	B-NP
intake 	intake 	 NN	I-NP
.  	.  	 .	O
An  	An  	 DT	O
impaired  	impaired  	 JJ	O
incretin  	incretin  	 JJ	B-NP
system 	system 	 NN	I-NP
,  	,  	 ,	O
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
decreased  	decreased  	 JJ	O
responsiveness  	responsiveness  	 NN	O
to  	to  	 TO	O
GIP  	GIP  	 NNP	B-NP
and  	and  	 CC	O
markedly  	markedly  	 RB	O
reduced  	reduced  	 VBD	B-NP
GLP-1  	GLP-1  	 CD	I-NP
concentration 	concentration 	 NN	I-NP
,  	,  	 ,	O
occurs  	occurs  	 VBZ	O
in  	in  	 IN	O
individuals  	individuals  	 NNS	O
with  	with  	 IN	O
type  	type  	 NN	B-NP
2  	2  	 CD	I-NP
diabetes  	diabetes  	 NN	I-NP
mellitus  	mellitus  	 NNS	I-NP
( 	( 	 -LRB-	O
T2DM 	T2DM 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
administration  	administration  	 NN	B-NP
of  	of  	 IN	I-NP
GLP-1  	GLP-1  	 NNP	I-NP
improves  	improves  	 VBZ	O
glycemic  	glycemic  	 JJ	B-NP
control 	control 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
GLP-1  	GLP-1  	 NNP	B-NP
is  	is  	 VBZ	O
rapidly  	rapidly  	 RB	O
degraded  	degraded  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
enzyme  	enzyme  	 FW	B-NP
dipeptidyl  	dipeptidyl  	 FW	I-NP
peptidase-4  	peptidase-4  	 FW	I-NP
( 	( 	 -LRB-	O
DPP-4 	DPP-4 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Exenatide 	Exenatide 	 NNP	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
DPP-4-resistant  	DPP-4-resistant  	 FW	B-NP
exendin-4  	exendin-4  	 FW	I-NP
GLP-1  	GLP-1  	 FW	I-NP
receptor  	receptor  	 FW	I-NP
agonist 	agonist 	 FW	I-NP
,  	,  	 ,	O
exhibits  	exhibits  	 VBZ	O
the  	the  	 DT	O
glucoregulatory  	glucoregulatory  	 JJ	B-NP
actions  	actions  	 NNS	I-NP
of  	of  	 IN	I-NP
GLP-1  	GLP-1  	 NNP	I-NP
and  	and  	 CC	O
reduces  	reduces  	 JJ	O
body  	body  	 NN	O
weight  	weight  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
T2DM 	T2DM 	 CD	O
.  	.  	 .	O
It  	It  	 PRP	O
may  	may  	 MD	O
possess  	possess  	 VB	O
cardiometabolic  	cardiometabolic  	 JJ	B-NP
actions  	actions  	 NNS	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
potential  	potential  	 JJ	O
to  	to  	 TO	O
improve  	improve  	 VB	O
the  	the  	 DT	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk  	risk  	 NN	I-NP
profile  	profile  	 NN	I-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
T2DM 	T2DM 	 CD	O
.  	.  	 .	O
DPP-4  	DPP-4  	 NNP	B-NP
inhibitors  	inhibitors  	 VBD	I-NP
such  	such  	 JJ	O
as  	as  	 IN	O
sitagliptin  	sitagliptin  	 NN	B-NP
and  	and  	 CC	O
saxagliptin  	saxagliptin  	 JJ	B-NP
increase  	increase  	 NN	I-NP
endogenous  	endogenous  	 VBD	O
GLP-1  	GLP-1  	 CD	B-NP
concentration  	concentration  	 NN	I-NP
and  	and  	 CC	O
demonstrate  	demonstrate  	 VB	O
incretin-associated  	incretin-associated  	 JJ	B-NP
glucoregulatory  	glucoregulatory  	 JJ	I-NP
actions  	actions  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
T2DM 	T2DM 	 CD	O
.  	.  	 .	O
DPP-4  	DPP-4  	 NNP	B-NP
inhibitors  	inhibitors  	 NNS	I-NP
are  	are  	 VBP	O
weight  	weight  	 NN	B-NP
neutral 	neutral 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
growing  	growing  	 VBG	B-NP
understanding  	understanding  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
roles  	roles  	 NNS	O
of  	of  	 IN	O
incretin  	incretin  	 JJ	B-NP
hormones  	hormones  	 NNS	I-NP
in  	in  	 IN	O
T2DM  	T2DM  	 NNP	O
may  	may  	 MD	O
further  	further  	 RB	O
clarify  	clarify  	 VB	O
the  	the  	 DT	O
application  	application  	 NN	O
of  	of  	 IN	O
incretin-based  	incretin-based  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
strategies 	strategies 	 NNS	I-NP
.  	.  	 .	O
